ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its compound ETS-006. The designation is for the treatment of pleural mesothelioma (PM), a rare and aggressive form of cancer.
Development and Potential of ETS-006
ETS-006 is an in-house developed oral YAP/TEAD protein-protein interaction (PPI) inhibitor that has shown excellent pharmacokinetics and robust anti-tumor activity in cellular and in vivo studies. The drug’s potential extends to the treatment of various tumors, including malignant pleural mesothelioma, breast cancer, gynecological cancer, sarcoma, and head and neck squamous cell carcinoma.
Clinical Filings and Future Prospects
ETERN Therapeutics is on the verge of submitting clinical filings for ETS-006 in both China and the United States, marking a significant step towards bringing this innovative treatment to patients in need. The FDA’s Orphan Drug Designation is expected to facilitate the development and approval process, potentially expediting the drug’s availability to patients with PM and other targeted cancers.-Fineline Info & Tech
Leave a Reply